Subscribe

Monitoring Drug Levels and ADAbs Benefits Cost, Improved Treatment Decision-Making

Web Exclusives - In the News

According to the authors of a recent study, although monitoring of anti-drug antibodies (ADAbs) or serum concentrations of biologicals in rheumatoid arthritis treatments could explain efficacy loss, and help with choosing subsequent medication, such monitoring of tumor necrosis factor (TNF)-α blockers is not generally done on a routine basis in current clinical practices. They have, however, demonstrated the cost-benefits of routine monitoring of drug levels and ADAbs in clinical practice, which they report can in turn improve the decision-making process of using TNF-α blockers.

Finland-based researchers estimating the likelihoods of optimal and nonoptimal treatment decisions whether or not infliximab or adalimumab drug trough level and ADAbs are tested in rheumatoid arthritis gathered drug levels and ADAbs concentration data of 486 and 1137 samples from Finnish patients taking adalimumab and infliximab, respectively. The investigators also intended to model cost-effectiveness of performing routine monitoring of this sort

Among samples from patients who were treated with adalimumab and infliximab, drug levels were in the target range of 42.0% and 50.4%, and ADAbs were detected in approximately 20.0% and 13.5%, respectively. In patients with low adalimumab or infliximab drug levels, ADAbs were found in 52.3% and 41.3%, respectively. Monitoring data were then merged into probabilities for making optimal treatment decisions.

During 3 to 6 months, the researchers used a scenario with 100 hypothetical patients to model the economic impact of clinical decision-making. The model consisted of drug level and ADAbs cost-saving measurements combined and compared with the non-testing scenario when monitoring results affected treatment decisions of ≥2 to 5 of 100 patients (a proportion that is easily exceeded in real-life clinical practice).

According to the authors, ineffective treatment of 5 patients for 3 months or 2.5 patients for 6 months costs approximately $24,758. When only 2.5 to 5 of 100 patients were treated nonoptimally for 3 to 6 months, routine measurement of drug levels and ADAbs proved to be cost-saving compared with the non-testing scenario.

“Our study indicates that the probability of nonoptimal drug treatment decision is noteworthy among the Finnish patients using infliximab and adalimumab if the data on individual DLs and ADAbs are not available,” the study authors reported. “Even at very low probability of nonoptimal decision, the systematic measurement of DLs and ADAbs seems to be cost-saving.”




Reference

  1. Laine J, Jokiranta TS, Eklund KK, et al. Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers. Biologics. 2016;10:67-73.
Related Items
FDA Approves First Tissue-Engineered Autologous Cellularized Scaffold Product for the Repair of Cartilage Defects
Web Exclusives published on December 15, 2016 in FDA Approvals, News & Updates, In the News
Abuse-Deterrent Oxycodone Extended-Release Capsules Approved for Chronic Pain
Web Exclusives published on November 7, 2016 in FDA Approvals, News & Updates, In the News
Adalimumab Biosimilar Approved for Multiple Inflammatory Indications
Web Exclusives published on September 27, 2016 in FDA Approvals, News & Updates, In the News
Biosimilar to Etanercept FDA Approved for Inflammatory Diseases
Web Exclusives published on September 12, 2016 in FDA Approvals, News & Updates, In the News
FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer
Web Exclusives published on June 13, 2016 in FDA Approvals, News & Updates, In the News
FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors
Web Exclusives published on June 13, 2016 in FDA Approvals, News & Updates, In the News
Clinical Efficacy, Safety Maintained for Up to 5 Years with Tocilizumab Use
Web Exclusives published on May 24, 2016 in In the News
Venclexta FDA Approved for Patients with CLL
Web Exclusives published on April 18, 2016 in FDA Approvals, News & Updates, In the News
FDA Approves Infliximab Biosimilar for Multiple Indications
Web Exclusives published on April 14, 2016 in FDA Approvals, News & Updates, In the News
Ixekizumab FDA-Approved for Patients with Plaque Psoriasis
Web Exclusives published on March 31, 2016 in FDA Approvals, News & Updates, In the News
Last modified: March 7, 2019
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology